F8 and hemophilia A: Emicizumab is a subcutaneously administered, bispecific, humanized monoclonal antibody that substitutes for missing or defective FVIII by bridging activated FIX and FX to allow the coagulation cascade to continue in people with hemophilia A [1,15,16].